학술논문
Rapid response of erythrodermic pityriasis rubra pilaris to tildrakizumab.
Document Type
Academic Journal
Author
Villa-Gonzalez JM; Department of Dermatology at Cruces University Hospital, Barakaldo, Biscay, Spain.; Gonzalez-Hermosa MR; Department of Dermatology at Cruces University Hospital, Barakaldo, Biscay, Spain.; Atxutegi-Ayesta X; Department of Dermatology at Cruces University Hospital, Barakaldo, Biscay, Spain.; Ratón Nieto JA; Department of Dermatology at Cruces University Hospital, Barakaldo, Biscay, Spain.; Gardeazabal García J; Department of Dermatology at Cruces University Hospital, Barakaldo, Biscay, Spain.; Lasa Elgezua O; Department of Dermatology at Cruces University Hospital, Barakaldo, Biscay, Spain.
Source
Publisher: Oxford University Press Country of Publication: England NLM ID: 7606847 Publication Model: Print Cited Medium: Internet ISSN: 1365-2230 (Electronic) Linking ISSN: 03076938 NLM ISO Abbreviation: Clin Exp Dermatol Subsets: MEDLINE
Subject
Language
English
Abstract
Competing Interests: Conflicts of interest J.M.V.-G. reported receiving support for attending meetings from Almirall, Novartis, UCB, Sanofi/Genzyme, Avène, Lilly, LEO Pharma and Janssen. M.R.G.-H. reported receiving support for attending meetings from Almirall, Novartis, UCB, Sanofi/Genzyme, Lilly, LEO Pharma and Janssen; and receiving honoraria for presentations from Sanofi/Genzyme and LEO Pharma. X.A.-A. reported receiving support for attending meetings from UCB, Novartis, La Roche Posay, Avène and Lilly. J.A.R. reported receiving support for attending meetings from Sanofi, Almirall, LEO and Lilly; and receiving honoraria for presentations from Sanofi, Lilly, LEO, AbbVie and Boehringer. J.G.G reported receiving support for attending meetings from Almirall, Novartis, Sanofi/Genzyme, Lilly, LEO Pharma and Janssen; and receiving honoraria for presentations from UCB, Lilly, LEO Pharma and Boehringer Ingelheim. O.L.E. reported receiving support for attending meetings from Almirall, AbbVie, Lilly, LEO Pharma, Galderma, Biofrontera and Janssen.